Leerink Partnrs Has Positive Outlook for HALO Q4 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Investment analysts at Leerink Partnrs upped their Q4 2025 earnings estimates for shares of Halozyme Therapeutics in a research note issued on Tuesday, February 18th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $1.66 per share for the quarter, up from their prior estimate of $1.57. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share.

Other analysts also recently issued reports about the stock. Benchmark reaffirmed a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. HC Wainwright boosted their price target on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Wednesday. JMP Securities boosted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Finally, Wells Fargo & Company lowered their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $57.75 on Friday. Halozyme Therapeutics has a 52-week low of $37.73 and a 52-week high of $65.53. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The company has a market capitalization of $7.11 billion, a P/E ratio of 16.84, a P/E/G ratio of 0.42 and a beta of 1.25. The company has a fifty day moving average of $53.46 and a 200-day moving average of $54.64.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new position in shares of Halozyme Therapeutics in the fourth quarter valued at about $128,000. Novem Group purchased a new position in shares of Halozyme Therapeutics during the fourth quarter valued at about $841,000. Voloridge Investment Management LLC purchased a new position in shares of Halozyme Therapeutics during the fourth quarter valued at about $876,000. Two Sigma Advisers LP purchased a new position in shares of Halozyme Therapeutics during the fourth quarter valued at about $282,000. Finally, Two Sigma Investments LP increased its position in shares of Halozyme Therapeutics by 403.0% during the fourth quarter. Two Sigma Investments LP now owns 247,030 shares of the biopharmaceutical company’s stock valued at $11,811,000 after buying an additional 197,918 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.